The majority of TP53-mutated MDS patients with genomic and/or chromosome 17 abnormalities are “multi-hit,” with 24% with multiple mutations, 22% with deletion mutations, and 21% with copy number heterozygous deletions (66, 69, 70). Here, TP53 is linked to myelodysplastic syndrome.